Holen Sie sich die Stockscreener-App
0.5498
19.00%
0.0878
Vorhandelsmarkt:
.56
0.0102
+1.86%
Schlusskurs vom Vortag:
$0.462
Offen:
$0.4866
24-Stunden-Volumen:
181.30K
Relative Volume:
0.63
Marktkapitalisierung:
$1.83M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+25.50%
1M Leistung:
-9.17%
6M Leistung:
-92.43%
1J Leistung:
-99.13%
1-Tages-Spanne:
$0.4849
$0.5499
1-Wochen-Bereich:
$0.38
$0.5499
52-Wochen-Spanne:
$0.3666
$108.00
Psyence Biomedical Ltd Stock (PBM) Company Profile
Firmenname
Psyence Biomedical Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie PBM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PBM
Psyence Biomedical Ltd
|
0.5498 | 1.83M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Psyence Biomedical Ltd Aktie (PBM) Neueste Nachrichten
Psyence Biomedical Faces Nasdaq Delisting Amid Shareholder Approval for Reverse Stock Split - TipRanks
Psyence BioMed gets Nasdaq notice for non-compliance - MSN
Psyence Group consolidates its shares - Crain's Chicago Business
Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency - TradingView
Psyence BioMed invests half a million into natural psychedelics operator PsyLabs - Mugglehead Magazine
Psyence BioMed boosts stake in PsyLabs with $500k investment By Investing.com - Investing.com Nigeria
Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement - Newsfile
Psyence Biomedical Transitions CRO for Psilocybin Trial in April 2025 - TipRanks
Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia - Newsfile
Major Expansion: Psyence's Breakthrough Cancer Mental Health Trial Targets Untreated Disorder - Stock Titan
Psyence Biomedical reports corporate update By Investing.com - Investing.com Australia
Psyence Biomedical reports corporate update - Investing.com
Psyence BioMed Advances in Psychedelic Medicine with Strategic Growth and Clinical Trials - TipRanks
Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing - TradingView
Psyence Biomedical Announces Special Shareholder Meeting for Share Consolidation - TipRanks
Psyence's Game-Changing Phase IIb Trial Takes On Cancer Mental Health Crisis - Stock Titan
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein - The Manila Times
Psyence Biomedical Ltd. (NASDAQ:PBMWW) Short Interest Down 13.1% in February - Defense World
Psyence Biomed expands advisory board with psychopharmacology expert By Investing.com - Investing.com Australia
Psyence Biomed expands advisory board with psychopharmacology expert - Investing.com India
Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein - Newsfile
Top Columbia Psychiatrist Joins Psyence's Psilocybin Clinical Trial Team - StockTitan
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board - The Manila Times
Psyence Biomedical files to sell 13.81M common shares for holders - MSN
Psyence Biomedical Ltd Files For Mixed Shelf Of Up To $75LN -March 04, 2025 at 04:48 pm EST - Marketscreener.com
Psyence Biomedical Ltd Files For Mixed Shelf Of Up To $75LN - TradingView
Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board - GlobeNewswire
Can This Johns Hopkins Psychedelics Expert Accelerate Psyence's Psilocybin Breakthroughs? - StockTitan
Psyence Biomedical Ltd (PBM) Stock: A Value Analysis - The News Heater
Ratio Analysis: Unpacking Psyence Biomedical Ltd (PBM)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Psyence Biomedical Adjusts Financials for Reverse Stock Split - TipRanks
Short Interest in Psyence Biomedical Ltd. (NASDAQ:PBMWW) Decreases By 41.0% - Defense World
Psyence enters into $25M common stock purchase agreement with White Lion Capital - MSN
Psyence Biomedical Issues Pre-Funded Share Purchase Warrant - TipRanks
Psyence Biomed Announces Closing of $2.0 Million Private Placement - The Manila Times
Psyence Biomed (PBM) Raises $2M in Private Placement with Warrant Coverage, Led by H.C. Wainwright - StockTitan
Psyence Biomedical Regains Nasdaq Compliance, Fortifying Market Position - Yahoo Finance
Psyence Biomed announces $2 million private placement By Investing.com - Investing.com Nigeria
Finanzdaten der Psyence Biomedical Ltd-Aktie (PBM)
Es liegen keine Finanzdaten für Psyence Biomedical Ltd (PBM) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.24%
36.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):